Embrace the new MATRIX: unlock 4 evidence-based FREE resources to omnichannel success!
News
Entering the Matrix of omnichannel engagement is a daunting prospect for biopharma. But in the Never Normal, where customer expectations are changing all the time, an agile go-to-market strategy is a must. It’s a red pill/blue pill choice. Would you go for red – and accept the painful truth of the need to adapt to a new reality? Or do you choose blue – returning to the alternate reality of an old normal on borrowed time?
Across Health’s evidence-based 4-step toolkit is custom-designed to help biopharma companies plan and execute OCE campaigns for the Never Normal. Start the program today and unlock 4 evidence-based resources for omnichannel success in the Never Normal.
Cookies are important for the proper functioning of our website. To improve your experience, we use cookies to remember settings, collect statistics to optimize site functionality, and deliver content tailored to your interests. Click Agree and close to accept cookies and go directly to the website. You can also refuse or check our cookie policy to see detailed descriptions of the types of cookies we use on our site.
To register your interest in joining the tour, and to comply with GDPR so we may send you future emails, please fill out the following information and complete the consent section at the bottom.
This site uses cookies to provide you with a more responsive and personalised service. Click on ‘Accept and close’ to accept all cookies or click ‘Configure Cookies’ to modify your cookie preferences.
Please read our Cookie policy for more information on the cookies we use.
These cookies or other identifiers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
ActiveInactive
Functional cookies:
The website uses functional cookies. Those cookies make it easier for our website to work, make them more pleasant for visitors, and ensure that you have a more personalized browsing experience (e.g. language choice). These cookies also enable us to personalise our content for you and remember your preferences. Across ensures that these cookies will not be used for a longer period than necessary for achieving this purpose. It is possible for you to delete these cookies at any time.
ActiveInactive
Performance cookies:
We use performance cookies to obtain information about visitors' use of our website, in order to improve the content of our website, adapt them to the wishes of visitors, and make them more user-friendly. For instance, there is a cookie that counts the number of unique visitors, and a cookie that keeps track of the most popular pages. For analyses of the use made of our website we also rely on Google Analytics, which use cookies for this as well.
ActiveInactive
Advertisement cookies:
These cookies record your visit to our website, the pages you have visited and the links you have followed. We will use this information to make our website more relevant to your interests. Advertisement cookies do not contain personal data.
Submit your details via this short form and you will be invited by one of our experts for a free 30-minute call to explore how Navigator365TM can provide an answer to your ambitions, needs and challenges.
Across Health, along with the entire Precision Value & Health team (of which we have been a part since February 2021), is now unified under one name: Precision AQ.
Having joined forces with over 1,200 life-science experts, advisors and creatives across 100+ diverse fields, we invite you to visit us at our new website to see how we are continuing to partner with our clients to deliver evidence-based omnichannel engagement strategies while empowering access to life-changing medicine for all
To find out more about our new global services and unified mission, read our publication here.
Entering the Matrix of omnichannel engagement is a daunting prospect for biopharma. But in the Never Normal, where customer expectations are changing all the time, an agile go-to-market strategy is a must. It’s a red pill/blue pill choice. Would you go for red – and accept the painful truth of the need to adapt to a new reality? Or do you choose blue – returning to the alternate reality of an old normal on borrowed time?